LEADER 03790nam 2200901z- 450 001 9910557287703321 005 20231214133224.0 035 $a(CKB)5400000000041163 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68933 035 $a(EXLCZ)995400000000041163 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPharmacogenomics and Personalized Medicine 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (208 p.) 311 $a3-03936-730-7 311 $a3-03936-731-5 330 $aPharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient?s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including a study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of inter-individual variability in drug metabolism. In this book, we have collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastructures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics. 606 $aMedicine$2bicssc 610 $aCYP2C9 610 $aVKORC1 610 $awarfarin 610 $awarfarin initiation phase of therapy 610 $aINR 610 $apharmacogenetics study 610 $apharmacogenomics 610 $apharmacogenetics 610 $agenotype 610 $aphenotype 610 $aalleles 610 $aprecision medicine 610 $apharmacotranscriptomics 610 $ahigh-throughput analysis 610 $achildhood acute lymphoblastic leukemia 610 $aclopidogrel 610 $aacenocoumarol 610 $aCDSS 610 $aimplementation 610 $aazathioprine 610 $ainflammatory bowel disease 610 $aglutathione-S transferase 610 $apharmacokinetics 610 $anucleoside analogs 610 $amicroRNAs 610 $agene expression 610 $adrug resistance 610 $aAML 610 $acisplatin 610 $anephrotoxicity 610 $akidney injury 610 $agenetic polymorphisms 610 $apre-emptive 610 $apanel 610 $abreast cancer subtype 610 $amiRNA 610 $apathway 610 $acrosstalk network 610 $aprecision drugs 610 $aovarian cancer 610 $aplatinum resistance 610 $afocal copy number alterations 610 $awhole exome sequencing 610 $apersonalized medicine 610 $ahuman genetics 610 $apharmacology 615 7$aMedicine 700 $aCecchin$b Erika$4edt$01281270 702 $aStocco$b Gabriele$4edt 702 $aCecchin$b Erika$4oth 702 $aStocco$b Gabriele$4oth 906 $aBOOK 912 $a9910557287703321 996 $aPharmacogenomics and Personalized Medicine$93018447 997 $aUNINA